Drug profile · INN
latanoprost
APO-LATANOPROST
latanoprost (APO-LATANOPROST) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — latanoprost
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
latanoprost (APO-LATANOPROST) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid FP receptor agonist
Primary target: Prostaglandin F2-alpha receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is latanoprost?
latanoprost (APO-LATANOPROST) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for latanoprost?
APO-LATANOPROST is a marketed brand name for latanoprost. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of latanoprost?
latanoprost has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.